tiprankstipranks
Bruker Corp (BRKR)
NASDAQ:BRKR

Bruker (BRKR) Stock Price & Analysis

304 Followers

BRKR Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$53.72 - $94.86
Previous Close$74.24
Volume67.00
Average Volume (3M)926.98K
Market Cap
$10.90B
Enterprise Value$11.69B
Total Cash (Recent Filing)$488.30M
Total Debt (Recent Filing)$1.36B
Price to Earnings (P/E)27.1
Beta1.02
Aug 01, 2024
Dividend Yield0.27%
Share Statistics
EPS (TTM)2.74
Shares Outstanding145,335,376
10 Day Avg. Volume1,615,441
30 Day Avg. Volume926,978
Standard Deviation0.10
R-Squared0.43
Alpha0.00423
Financial Highlights & Ratios
Price to Book (P/B)22.46
Price to Sales (P/S)3.64
Price to Cash Flow (P/CF)12.70
P/FCF Ratio14.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.29
Enterprise Value/Gross Profit3.94
Enterprise Value/Ebitda17.53
Forecast
Price Target Upside15.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say
Growth And Market PositionBRKR's continued path on strengthening its post genomics era capabilities through strategic acquisitions, including NSTG’s spatial instruments, indicates a commitment to building a robust spatial market portfolio.
Innovation And Technology ImpactCIC bioGUNE announced installation of one of BRKR's ultra-high field 1.0 GHz Ascend Evo NMR systems, which could add to core growth and expand research in personalized medicine, including metabolomics, biomarkers for rare diseases & drug discovery.
Legal And Sales OutlookGerman Federal Patent Court invalidated the patent used as the basis of an injunction on CosMx sales in Germany, which could alleviate investor concerns about litigation overhang.
Bears Say
Acquisition ImpactThe recent acquisition of NSTG is expected to be EPS dilutive this year, impacting earnings per share.
Financial RisksBefore the acquisition, NSTG was liable for significant damages due to patent infringement, which indicates potential financial risks associated with the deal.
Revenue ConcernsRevenues were affected by approximately $15M shifted into the next quarter, causing a top-line headwind.
---

Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

BRKR FAQ

What was Bruker Corp’s price range in the past 12 months?
Bruker Corp lowest stock price was $53.72 and its highest was $94.86 in the past 12 months.
    What is Bruker Corp’s market cap?
    Currently, no data Available
    When is Bruker Corp’s upcoming earnings report date?
    Bruker Corp’s upcoming earnings report date is Aug 01, 2024 which is in 79 days.
      How were Bruker Corp’s earnings last quarter?
      Bruker Corp released its earnings results on May 02, 2024. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.465 by $0.065.
        Is Bruker Corp overvalued?
        According to Wall Street analysts Bruker Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Bruker Corp pay dividends?
          Bruker Corp pays a Quarterly dividend of $0.05 which represents an annual dividend yield of 0.27%. See more information on Bruker Corp dividends here
            What is Bruker Corp’s EPS estimate?
            Bruker Corp’s EPS estimate is $0.54.
              How many shares outstanding does Bruker Corp have?
              Bruker Corp has 145,335,370 shares outstanding.
                What happened to Bruker Corp’s price movement after its last earnings report?
                Bruker Corp reported an EPS of $0.53 in its last earnings report, beating expectations of $0.465. Following the earnings report the stock price went down -11.312%.
                  Which hedge fund is a major shareholder of Bruker Corp?
                  Among the largest hedge funds holding Bruker Corp’s share is Iron Triangle Partners LP. It holds Bruker Corp’s shares valued at 33M.
                    ---

                    Company Description

                    Bruker Corp

                    Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the Bruker Scientific Instruments (BSI), and Bruker Energy and Supercon Technologies (BEST) segments. The BSI segment comprises of the Bruker BioSpin Group, the Bruker CALID Group, and the Bruker Nano Group. The BEST segment designs, manufactures, and distributes superconducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications. The company was founded by Gunther Laukien in 1961 and is headquartered in Billerica, MA.
                    ---

                    BRKR Company Deck

                    ---

                    BRKR Earnings Call

                    Q1 2024
                    0:00 / 0:00
                    ---

                    BRKR Stock 12 Month Forecast

                    Average Price Target

                    $86.50
                    ▲(15.30% Upside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"57":"$57","80":"$80","103":"$103","68.5":"$68.5","91.5":"$91.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":102,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$102.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":86.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$86.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$74.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[57,68.5,80,91.5,103],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.04,72.49846153846154,74.95692307692308,77.41538461538462,79.87384615384616,82.3323076923077,84.79076923076923,87.24923076923076,89.70769230769231,92.16615384615385,94.62461538461538,97.08307692307693,99.54153846153847,{"y":102,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.04,71.30615384615385,72.5723076923077,73.83846153846154,75.10461538461539,76.37076923076924,77.63692307692308,78.90307692307692,80.16923076923078,81.43538461538462,82.70153846153846,83.96769230769232,85.23384615384616,{"y":86.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,70.04,70.3446153846154,70.64923076923077,70.95384615384616,71.25846153846155,71.56307692307692,71.86769230769231,72.1723076923077,72.47692307692309,72.78153846153846,73.08615384615385,73.39076923076924,73.69538461538461,{"y":74,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73.54,"date":1683849600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.24,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.78,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.07,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.85,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.7,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.74,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.02,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.39,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.12,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.33,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.42,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.04,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Agilent
                    AbbVie
                    Abbott Laboratories
                    Abeona Therapeutics

                    Best Analysts Covering BRKR

                    1 Year
                    1 Year Success Rate
                    16/23 ratings generated profit
                    70%
                    1 Year Average Return
                    +13.88%
                    reiterated a buy rating 3 months ago
                    Copying Brandon Couillard's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +13.88% per trade.
                    Popular Stocks
                    ---
                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis